Poster Number
|
Title of Presentation |
First Name
|
Last Name
|
Clinical Care
|
| 1
|
An Immunochromatographic Test for Measurement of Alanine Aminotransferase (ALT) at Point of Care
|
David
|
Anderson
|
| 2
|
Fibroscan Screening in General Practice: Results from a Pilot Program
|
David
|
Baker
|
| 3 |
Real Life Experience of Prescribing Direct Acting Agents (DAA’s) In a Primary Care Based General Practitioner Liver Clinic in Rural NSW - Does It Work?
|
Anne
|
Balcomb
|
| 4 |
Introduction of an Australian First Multidisciplinary Approach to the Initiation of Direct Acting Antivirals Involving Pharmacist Led Medication Reviews |
Millicent
|
Ballancin |
| 5 |
Hepatitis C Specialist Social Worker in a Community Clinic: One of a Kind in New Zealand |
Marilyn |
Brown |
| 6 |
APRI versus Fibroscan Score for Assessing Advanced Liver Diseases in a Communty-Based Cohort with Chronic HCV Infection |
Joseph
|
Doyle
|
| 7 |
Eliminating Hepatitis C Transmission by Enhancing Care and Treatment among HIV Co-Infected Individuals: The Co-EC Study |
Joseph
|
Doyle
|
| 8 |
Incorporating Overdose Management into Routine Care of People who Inject Drugs who are Undergoing Hepatitis C Treatment with direct Acting Antivirals
|
Rosie |
Gilliver
|
| 9 |
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients with Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials
|
Jason
|
Grebely |
| 10 |
Ledipasvir/Sofosbuvir for 8 Weeks – A Comparative Analysis of Clinical Trial Efficacy versus Real World Effectiveness
|
Krispin
|
Hajkowicz
|
| 11 |
Sofosbuvir/Velpatasvir for 12 Weeks Results In High Svr12 Rates in Subjects with Negative Predictors of Response to Treatment
|
Barbara |
Leggett |
| 12 |
Hepatitis C Treatment Uptake in a Single Tertiary Based Viral Hepatitis Service Following Availability of Interferon-Free Treatments |
Gail |
Matthews |
| 13 |
A Nurse-Led Model of Care for Prisoners with Viral Hepatitis: Experience from the Victorian Statewide Hepatitis Program
|
Lucy |
McDonald |
| 14 |
Treating Patients with Hepatitis C Genotype 1 Using Viekira Pak™ in the “Real World” – An Australian Nursing Perspective |
Saroj |
Nazareth |
| 15 |
Hepatitis C Virus Infection: Barriers to Achieving Treatment
|
Leigh-Anne
|
Pokino
|
| 16 |
Development of the Australasian Hepatology Association’s Consensus Guidelines for the Provision of Adherence Support to People with Hepatitis C Taking Direct Acting Antivirals
|
Jacqui
|
Richmond
|
| 17 |
High SVR Rates with ABT-493 + ABT-530 Co-Administered for 8 Weeks in Non-Cirrhotic Patients with HCV Genotype 3 Infection |
Simone |
Strasser
|
| 18 |
Training of Health Professionals Working In Primary Care for the Active Search for Patients with Hepatitis C and Early Diagnosis |
Adauto
|
Vieira de Almeida
|
| 19 |
Hepatitis B Vaccination Status among Physical Therapy and Pharmacology Graduate Students
|
Adauto
|
Vieira de Almeida
|
| 20 |
Preliminary Data from the Prime Study; A Randomised Controlled Trial of Community Vs Hospital Direct Acting Antiviral Therapy
|
Amanda
|
Wade
|
| 21 |
New Frontiers for Hepatitis C Treatment: Exploring the “In Consultation” Experience
|
Sally
|
Watkinson
|
| 22 |
Early Local Western Australian Experience with Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir +/- Ribavirin in Genotype 1 Hepatitis C Patients and its Impact on Liver Fibrosis and Liver Inflammation
|
John |
Wong |
| 23 |
Scaling up Hepatitis Treatment in the NSW Custodial Setting – Challenges and Opportunities |
James |
Wood |
Epidemiology, Public Health and Prevention
|
| 24 |
Hepatitis B contact tracing: what works |
Thalia |
Ash
|
| 25 |
Hepatitis C Risk Behaviour among People Who Inject Pharmaceutical Opioids
|
Louise
|
Geddes
|
| 26 |
Chronic Hepatitis C Burden and Care Cascade in Australia in the Era of Interferon-Based Treatment
|
Behzad
|
Hajari
|
| 27 |
Mums to B: Care for Women with Hepatitis B
|
Aurora
|
Tang
|
| 28 |
HepCheck 1-2-3: Integrated Hepatitis Care for People Affected by Homelessness
|
Kyle
|
Leadbeatter
|
| 29 |
Depression and its Association with Hepatitis B Status: Findings from 0.5 Million Chinese Adults
|
Uling
|
Liu
|
| 30 |
Training of Community Health Agents for Active Search of Patients with Viral Hepatitis
|
Flavia
|
Paro
|
| 31 |
Hepatitis B Vaccination among Primary Health Care Workers in a City of Brazil
|
Flavia
|
Paro
|
| 32 |
Knowledge about Viral Hepatitis among Primary Health Care Workers in Brazil
|
Flavia
|
Paro
|
| 33 |
Epidemiological Profile of Organ Donors for Transplantation in Hospitals of Brazil
|
Flavia
|
Paro
|
| 34 |
Identifying the Essential Components of a Public Health Response to Hepatitis B: Tasmania
|
Jack |
Wallace
|
| 35 |
Survival Following Hepatocellular Carcinoma among People with a HBV or HCV Notification in New South Wales, Australia between 2000 and 2014
|
Reem
|
Waziry |
Community and Social Research
|
| 36 |
Increasing Access to Training for Regional NSP Workers: NSP Online Orientation and Training Package
|
Judith
|
Bevan
|
| 37 |
Let us Build Bridges and Dismantle Inequitable Health Practices
|
Bronwyn
|
Briggs
|
| 38 |
Being Strong: Hepatitis, Liver Health and the NSW Corrective Services Intranet
|
Grace
|
Crowley
|
| 39 |
A Qualitative Study of the Perceptions of Interferon-Free Therapy for Hepatitis C Virus Infection among People who Inject Drugs: The Liverlife Study
|
Evan |
Cunningham
|
| 40 |
Viral Hepatitis in the Media: The Potential Negative Effects of Poor Reporting
|
Yvonne
|
Drazic |
| 41 |
CHAT in Action Creating Change
|
Jaye
|
Hinchliffe
|
| 42 |
Health Promotion with Australian Afghan Community; How Building Relationships with Community Groups Assists with Health Promotion Activities
|
Sayed |
Jawid
|
| 43 |
Fostering A Vibrant Peer Workforce
|
Kyle
|
Leadbeatter
|
| 44 |
The Hepatitis Infoline: Community-Led and Community-Leading Developments in the Viral Hepatitis Community
|
Kyle
|
Leadbeatter
|
| 45 |
Is there a Need for Hepatitis-Informed Counselling in the Era of New DAA Treatments?
|
Kyle
|
Leadbeatter
|
| 46 |
The Success of Hepatitis B Campaign Within Africans/ Cultural and Linguistic Diverse (CALD) Living In South Australia
|
Martin
|
Manariyo
|
| 47 |
Eliminating Hepatitis C in the Australian Bleeding Disorders Population: An Evolving Health Promotion Strategy
|
Suzanne
|
O'Callaghan
|
| 48 |
Advocates in action: The work of Hepatitis Victoria
Community Advocates
|
Ross
Nafisa
|
Williams
Yuusf
|
| 49 |
Art inside the West: Collaborating With People in Custody
|
Gary
|
Irving
|
Basic Science |
| 50 |
Modelling the Effects of Targeted DAA Hepatitis C Virus Treatment Strategies Using a Molecular Transmission Network of People with Recent Infection
|
Sofia
|
Bartlett
|
| 51 |
HBV Core Promoter Mutants Activate Pi3k/AKT Signalling In Cell Culture, Promoting Hepatocarcinogenesis
|
Anis
|
Khan
|
| 52 |
Hepatitis C Virus Core Antigen and Dried Blood Spots as Simplified Hepatitis C Virus Diagnostic Tools
|
Francois
|
Lamoury
|
| 53 |
Hepatitis C Virus Core Antigen: A Simplified Treatment Monitoring Tool among those with Recent HCV Infection, Including for Post-Treatment Relapse
|
Francois
|
Lamoury
|
| 54 |
Deep Sequencing Shows that the Presence Of HBV BCP/Pc Variants Reduces the Rate of HBSAG Loss among HBEAG-Positive CHB Patients Treated with Long-Term Tenofovir DF Therapy
|
Margaret
|
Littlejohn
|
| 55 |
Refolding the Hepatitis C Virus E2 Glycoprotein to Enhance Immunogenicity
|
Lilian
|
Phu
|
| 56 |
Commitment to CD8+ T Cell Exhaustion and Loss of Memory T Cell Potential Develops during Primary Chronic HCV Infection
|
Mehdi
|
Rasoli Pirozyan
|
| 57 |
Trends of Hepatitis C Virus Epidemic in Australia and North America in 20th Century: Back Projections from Molecular Epidemiology
|
Chaturaka
|
Rodrigo
|
| 58 |
Viral Kinetic are Significantly Different In Basal Core Promoter and Precore Variants of Hepatitis B
|
Zina
|
Valaydon
|
| 59 |
Triterpenoid Saponin from Wedelia Calendulacea Protects against Ccl4 Induced Liver Injury by Inhibiting Nf-Κb Activation
|
Amita
|
Verma |
